D-0390-2024 Class II Ongoing
FDA drug recall D-0390-2024 was initiated by Eugia US LLC on Feb 20, 2024 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification for organic impurities The recall status is ongoing. Affected quantity: 335,940 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2024
- Initiation Date
- Feb 20, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 335,940 vials
Product description
Nicardipine Hydrochloride Injection (2.5mg/mL), US, 25mg per 10mL, 10mL Vial, Rx only, Distributed by: AuroMedics Pharma LLC 279 Princeton-Hightstown Rd. E. Windsor, NJ 08520 NDC 55150-183-10
Reason for recall
Failed Impurities/Degradation Specifications: Out of specification for organic impurities
Distribution pattern
Nationwide within the United States
Code information
Lot #: 3NC23002, Exp. Date 7/24; 3NC22013, 3NC22014, 3NC22015, 3NC22016, 3NC22017, 3NC22018, Exp. Date 2/24; 3NC22020, Exp. Date 3/24
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0390-2024
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026